Phase III long-term safety study of soluble ferric pyrophosphate (SFP) in dialysate in patients with chronic kidney disease receiving haemodialysis

Trial Profile

Phase III long-term safety study of soluble ferric pyrophosphate (SFP) in dialysate in patients with chronic kidney disease receiving haemodialysis

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2016

At a glance

  • Drugs Ferric pyrophosphate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions; Registrational
  • Sponsors Rockwell Medical Technologies
  • Most Recent Events

    • 19 Jan 2016 Data will be presented at the National Kidney Foundation Spring Clinical Meeting 2016, according to a Rochwell Medical Technologies media release.
    • 13 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top